Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy

被引:71
作者
Shintani, Yasuyo [1 ]
Sawada, Yoshihisa [1 ]
Inagaki, Takeshi [1 ]
Kohjimoto, Yasuo [1 ]
Uekado, Yasunari [1 ]
Shinka, Toshiaki [1 ]
机构
[1] Wakayama Med Univ, Dept Urol, Wakayama 6418509, Japan
关键词
bladder neoplasm; immunotherapy; intravesical instillation; Mycobacterium bovis;
D O I
10.1111/j.1442-2042.2007.01696.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: In order to clarify the initial step of the mechanism by which bacillus Calmette-Guerin (BCG) exhibits antitumor activity via the immune response induced in the bladder submucosa after intravesical BCG therapy for human bladder cancer, various cytokines secreted in the urine after BCG instillation were measured. Methods: After transurethral resection of bladder cancer, a 6-week course of BCG instillation was performed. At the first and sixth weeks' dosings, spontaneously excreted urine was collected before and 4, 8, and 24 h after BCG instillation. The urinary cytokines were determined by Sandwich enzyme-linked immunosorbent assay using monoclonal antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-1 beta, IL-8, interferon (IFN)-gamma, and IL-12. Results: After the BCG therapy, various cytokines, such as GM-CSF, TNF-alpha, G-CSF, IL-1 beta, IL-8, IFN-gamma, and IL-12 were secreted, comprising the immune response cascade. The mean urinary excretions of GM-CSF and TNF-alpha 4 h after the sixth week's instillation were significantly higher than the pre-instillation levels. There were no significant increases in the urinary IFN-gamma or IL-12 levels between 4 and 24 h after the sixth week's instillation. The TNF-alpha level 4 h after the sixth week's instillation had a strong tendency towards the absence of recurrence, with a mean follow-up of 54.1 months. The Kaplan-Meier curve showed the 2, 5, and 10-year recurrence-free survival rates were 72.4%, 65.8%, and 56.4%, respectively. conclusionsL We suggested that the urinary levels of TNF-alpha might be essential in antitumor activity after BCG therapy and might play an important role in the prevention of bladder tumor recurrence.
引用
收藏
页码:140 / 146
页数:7
相关论文
共 50 条
[41]   Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin [J].
Thalmann, GN ;
Sermier, A ;
Rentsch, C ;
Möhrle, K ;
Cecchini, MG ;
Studer, UE .
JOURNAL OF UROLOGY, 2000, 164 (06) :2129-2133
[42]   Vesicoureteral reflux after intravesical instillation of bacillus Calmette-Guerin against carcinoma in situ of the bladder [J].
Morita, T ;
Tokue, A .
UROLOGIA INTERNATIONALIS, 2004, 73 (03) :287-288
[43]   Bacillus Calmette-Guerin infection following intravesical instillation: Does the strain matter? [J].
Levi, L., I ;
Schlemmer, F. ;
de Castro, N. ;
Brun, O. ;
Veziris, N. ;
Argemi, X. ;
Roupret, M. ;
Launay, O. ;
Bergeron, A. ;
Gro, M. ;
Blanc, F-X ;
Blanche, P. ;
Bouvier, C. ;
Calestrapout, J. P. ;
De Jong, Z. ;
Dufour, S. ;
Eden, A. ;
Erb, C. ;
Fraisse, P. ;
Gagnard, J-C ;
Goudet, V ;
Goujard, C. ;
Groh, M. ;
Guigon, A. ;
Hocqueloux, L. ;
Issoufaly, T. ;
Kazitani, A. ;
Laugros, D. ;
Le Moing, V ;
Letang, N. ;
Lucht, F. ;
Mathe, L. ;
Melica, G. ;
Menard, A. ;
De Menthon, M. ;
Moachon, L. ;
Montsaint, H. ;
Morlat, P. ;
Naccache, J-M ;
Neau, D. ;
Nerault, N. ;
Sene, T. ;
Verhoest, G. ;
Vordos, D. ;
Vuotto, F. ;
Wyplosz, B. ;
Yaghi, N. .
MEDECINE ET MALADIES INFECTIEUSES, 2019, 49 (05) :350-355
[44]   PRESENCE OF ACTIVATED LYMPHOCYTES IN THE URINE OF PATIENTS WITH SUPERFICIAL BLADDER-CANCER AFTER INTRAVESICAL IMMUNOTHERAPY WITH BACILLUS CALMETTE-GUERIN [J].
DEBOER, EC ;
DEJONG, WH ;
VANDERMEIJDEN, APM ;
STEERENBERG, PA ;
WITJES, JA ;
VEGT, PDJ ;
DEBRUYNE, FMJ ;
RUITENBERG, EJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (06) :411-416
[45]   Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guerin instillations for superficial bladder cancer [J].
Kaneko, T ;
Fujita, K ;
Homma, Y .
INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (03) :294-295
[46]   Comparative study between intravesical gemcitabine versus bacillus Calmette-Guerin in high risk superficial bladder cancer [J].
Ali, M. H. ;
Elazab, M. E. ;
Salem, T. A. ;
Hussien, N. M. ;
Zaza, M. M. .
ONKOUROLOGIYA, 2025, 21 (01)
[47]   Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Review of complications and their treatment [J].
Paterson, DL ;
Patel, A .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1998, 68 (05) :340-344
[48]   Poly(I:C) potentiates Bacillus Calmette-Guerin immunotherapy for bladder cancer [J].
Ayari, Cherifa ;
Besancon, Marjorie ;
Bergeron, Alain ;
LaRue, Helene ;
Bussieres, Vanessa ;
Fradet, Yves .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (02) :223-234
[49]   Intravesical bacillus Calmette-Guerin combined with electromotive mitomycin for high-risk superficial bladder cancer [J].
Bochner, Bernard H. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (09) :474-475
[50]   Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer [J].
Hugar, Lee A. ;
Gilbert, Scott M. ;
Sexton, Wade J. ;
Kamat, Ashish M. ;
Li, Roger .
CURRENT OPINION IN UROLOGY, 2021, 31 (02) :160-169